PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design.
Broglio K, Kostakoglu L, Ward C, Mattiello F, Sahin D, Nielsen T, McGlothlin A, Elliott CF, Witzig T, Sehn LH, Trnĕný M, Vitolo U, Martelli M, Foster M, Wendelberger B, Nowakowski G, Berry DA.
Broglio K, et al. Among authors: foster m.
Leuk Lymphoma. 2022 Dec;63(12):2816-2831. doi: 10.1080/10428194.2022.2095624. Epub 2022 Jul 11.
Leuk Lymphoma. 2022.
PMID: 35815677